(541.7) Knockdown and Inhibition of Spleen Tyrosine Kinase Decreases mTORC1 Activity and Enhances Lysosomal Biogenesis and Autolysosomal Maturation in Pancreatic Cancer Cell Lines

Poster Board Number: B145

Michelle Pan (Boston University School of Medicine), Kevin Hua (Boston University School of Medicine), Akash Villait (Boston University School of Medicine), Angelina Zuger (Boston University School of Medicine), Minoo Rafati (Boston University School of Medicine), Ryan Chen (Boston University School of Medicine), Anurag Singh (Boston University School of Medicine)

In cancer, oncogene dependency is a phenomenon where a dominant driver oncogene promotes tumor cell proliferation and survival, and loss of this oncogene results in tumor cell death and, eventually, tumor regression. KRAS, a GTPase that regulates cell growth and proliferation, is an oncogene constitutively activated in over 90% of pancreatic cancer. However, clinically effective inhibitors of KRAS have been unsuccessful so efforts have been focused on identifying other potential targets associated with the KRAS signaling network. Spleen tyrosine kinase (SYK), which is expressed at high levels in KRAS-dependent pancreatic cancer cell lines, may be one of these targets. Our data indicate that SYK activates the mechanistic target of rapamycin kinase complex 1 (mTORC1), which promotes protein translation and cell growth. SYK activation also leads to decreased autolysosome count. In connecting SYK activation with increased mTORC1 activity and decreased autolysosome count, we hypothesis that the MiT/TFE transcription factors are involved. We propose that SYK inhibition in pancreatic cancer cells leads to reduced mTORC1 activity, which reduces phosphorylation of MiT/TFE transcription factors. The unphosphorylated MiT/TFE transcription factors may then enter the nucleus to activate genes for lysosomal biogenesis and autophagy. Autophagy is a process that recycles cellular macromolecules during nutrient deprivation by fusing autophagosomes and lysosomes, produced from lysosomal biogenesis, to generate autolysosomes. From our experiments, we were able to show that SYK inhibition blocks mTORC1-dependent phosphorylation of MITF and TFEB transcription factors, members of the MiT/TFE family. MITF and TFEB activation leads to increased autophagy due to autolysosomal biogenesis and accumulation. In summary, our studies of the SYK-mTORC1-autophagy pathway provide support to investigate SYK as a candidate therapeutic target for pancreatic cancer treatment.

Support or Funding Information

1. NIH/NCI K99/R00 - Anurag Singh (PI) 2. Boston University Dahod Breast Cancer Pilot Award - Anurag Singh (PI) 3. Boston Universitys Undergraduate Research Opportunities Program - Michelle Pan

1. NIH/NCI K99/R00 - Anurag Singh (PI)
2. Boston University Dahod Breast Cancer Pilot Award - Anurag Singh (PI)
3. Boston Universitys Undergraduate Research Opportunities Program - Michelle Pan